File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: Comparison of two consecutive cohorts of childhood acute myeloid leukemia in Hong Kong

TitleComparison of two consecutive cohorts of childhood acute myeloid leukemia in Hong Kong
Authors
KeywordsMedical sciences
Oncology medical sciences
Pediatrics
Issue Date2013
PublisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1545-5017/
Citation
The 45th Congress of the International Society of Paediatric Oncology (SIOP 2013), Hong Kong, China, 25-28 September 2013. In Pediatric Blood & Cancer, 2013, v. 60 S3, p. 74, abstract no. P-0084 How to Cite?
AbstractPURPOSE/OBJECTIVE: To review the clinical data and outcome of two consecutive cohorts of pediatric patients with acute myeloid leukemia (AML) treated with two different protocols prospectively at 5 oncology units under coordination of Hong Kong Paediatric Haematology & Oncology Study Group (HKPHOSG) MATERIALS AND METHODS: Cohort 1 was treated with modified UKAML XII regimen from 1995 to 2007 (13 years). We treated Cohort 2 from 2008 to 2012 (5 years) with NOPHO AML 2004 protocol as a collaborating group. Main differences with the latter protocol were D15 marrow blast count as risk factor, use of idarubicin instead of daunorubicin, higher cumulative dose of cytarabine, indication for transplant and donor selection. Acute promyelocytic leukemia and myeloid leukemia of Down syndrome were excluded. RESULTS: There are 104 cases in Cohort 1 and 53 in Cohort 2. Age distribution and median age (9.5 yr) are similar in the two cohorts. There are more female in Cohort 1 (53.8%) than Cohort 2 (37.7%). The FAB subtype distribution shows no obvious difference, but the number of patients with t(8;21) or AML1-ETO is higher in Cohort 1 (17.3%) than Cohort 2 (9.4%). There is no significant difference in induction death (Cohort 1: 2.9%; Cohort 2: 3.8%) and Complete Remission (CR) rate after induction (Cohort 1: 92.3%; Cohort 2: 94.3%). Relapse rates for Cohort 1 and 2 are 46.1% and 37.7% while total transplant rates are 55.8% and 45.3% respectively. The 5-yr event-free survival (Cohort 1:43.3%; Cohort 2: 46.7%) and overall survival (Cohort 1: 64.65%; Cohort 2: 64.6%) show no significant difference. The median follow up is 112.2 months for Cohort 1, and is 30.7 months for Cohort 2. CONCLUSIONS: The recent protocol (NOPHO AML 2004) has been able to achieve similar survival rates as the last protocol with fewer transplants and less daunorubicin. Different strategies to improve treatment outcome are needed in future.
DescriptionThis journal suppl. entitled: Supplement: SIOP Abstratcs: 45th Congress of the International Society of Paediatric Oncology (SIOP) ... 2013
Poster Session - Myeloid Leukemias: abstract no. P-0084
Persistent Identifierhttp://hdl.handle.net/10722/197714
ISSN
2015 Impact Factor: 2.634
2015 SCImago Journal Rankings: 1.505

 

DC FieldValueLanguage
dc.contributor.authorHa, SYen_US
dc.contributor.authorLee, Ven_US
dc.contributor.authorLi, CHen_US
dc.contributor.authorLuk, CWen_US
dc.contributor.authorLing, SCen_US
dc.contributor.authorCheuk, KLen_US
dc.contributor.authorShing, MMKen_US
dc.contributor.authorLi, CKen_US
dc.contributor.authorHasle, H-
dc.date.accessioned2014-05-29T08:45:06Z-
dc.date.available2014-05-29T08:45:06Z-
dc.date.issued2013en_US
dc.identifier.citationThe 45th Congress of the International Society of Paediatric Oncology (SIOP 2013), Hong Kong, China, 25-28 September 2013. In Pediatric Blood & Cancer, 2013, v. 60 S3, p. 74, abstract no. P-0084en_US
dc.identifier.issn1545-5009-
dc.identifier.urihttp://hdl.handle.net/10722/197714-
dc.descriptionThis journal suppl. entitled: Supplement: SIOP Abstratcs: 45th Congress of the International Society of Paediatric Oncology (SIOP) ... 2013-
dc.descriptionPoster Session - Myeloid Leukemias: abstract no. P-0084-
dc.description.abstractPURPOSE/OBJECTIVE: To review the clinical data and outcome of two consecutive cohorts of pediatric patients with acute myeloid leukemia (AML) treated with two different protocols prospectively at 5 oncology units under coordination of Hong Kong Paediatric Haematology & Oncology Study Group (HKPHOSG) MATERIALS AND METHODS: Cohort 1 was treated with modified UKAML XII regimen from 1995 to 2007 (13 years). We treated Cohort 2 from 2008 to 2012 (5 years) with NOPHO AML 2004 protocol as a collaborating group. Main differences with the latter protocol were D15 marrow blast count as risk factor, use of idarubicin instead of daunorubicin, higher cumulative dose of cytarabine, indication for transplant and donor selection. Acute promyelocytic leukemia and myeloid leukemia of Down syndrome were excluded. RESULTS: There are 104 cases in Cohort 1 and 53 in Cohort 2. Age distribution and median age (9.5 yr) are similar in the two cohorts. There are more female in Cohort 1 (53.8%) than Cohort 2 (37.7%). The FAB subtype distribution shows no obvious difference, but the number of patients with t(8;21) or AML1-ETO is higher in Cohort 1 (17.3%) than Cohort 2 (9.4%). There is no significant difference in induction death (Cohort 1: 2.9%; Cohort 2: 3.8%) and Complete Remission (CR) rate after induction (Cohort 1: 92.3%; Cohort 2: 94.3%). Relapse rates for Cohort 1 and 2 are 46.1% and 37.7% while total transplant rates are 55.8% and 45.3% respectively. The 5-yr event-free survival (Cohort 1:43.3%; Cohort 2: 46.7%) and overall survival (Cohort 1: 64.65%; Cohort 2: 64.6%) show no significant difference. The median follow up is 112.2 months for Cohort 1, and is 30.7 months for Cohort 2. CONCLUSIONS: The recent protocol (NOPHO AML 2004) has been able to achieve similar survival rates as the last protocol with fewer transplants and less daunorubicin. Different strategies to improve treatment outcome are needed in future.-
dc.languageengen_US
dc.publisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1545-5017/-
dc.relation.ispartofPediatric Blood & Canceren_US
dc.rightsPediatric Blood & Cancer. Copyright © John Wiley & Sons, Inc.-
dc.subjectMedical sciences-
dc.subjectOncology medical sciences-
dc.subjectPediatrics-
dc.titleComparison of two consecutive cohorts of childhood acute myeloid leukemia in Hong Kongen_US
dc.typeConference_Paperen_US
dc.identifier.emailHa, SY: syha@hku.hken_US
dc.identifier.emailCheuk, KL: cheukkld@hkucc.hku.hk-
dc.identifier.emailLi, CK: lichik@hkucc.hku.hk-
dc.identifier.doi10.1002/pbc.24719-
dc.identifier.hkuros229023en_US
dc.identifier.volume60-
dc.identifier.issueS3-
dc.identifier.spage74-
dc.identifier.epage74-
dc.publisher.placeUnited States-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats